We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$936M
1-Year Est. Return
195%
This Fund
S&P 500
This Quarter
Est. Return
-8.9%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$485M
AUM Growth
-$518M
(-52%)
Cap. Flow
-$436M
Cap. Flow
% of AUM
-89.85%
Top 10 Holdings %
Top 10 Hldgs %
43.79%
Holding
82
New
19
Increased
3
Reduced
37
Closed
17
Top Buys
| 1 |
Beam Therapeutics
BEAM
|
+$18.6M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$11.7M |
| 3 |
Cencora
COR
|
+$9.87M |
| 4 |
Teva Pharmaceuticals
TEVA
|
+$8.59M |
| 5 |
State Street SPDR S&P Biotech ETF
XBI
|
+$8.4M |
Top Sells
| 1 |
Intuitive Surgical
ISRG
|
+$33.8M |
| 2 |
Mirum Pharmaceuticals
MIRM
|
+$29.5M |
| 3 |
Acadia Healthcare
ACHC
|
+$26.1M |
| 4 |
Dianthus Therapeutics
DNTH
|
+$25.4M |
| 5 |
Jazz Pharmaceuticals
JAZZ
|
+$20.2M |
Sector Composition
| 1 | Healthcare | 98.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Boston Scientific
BSX
$64B
| $33.9M | 6.99% |
336,000
-179,000
| -35% | -$18M |
|
|
2
Dianthus Therapeutics
DNTH
$5.46B
| $31.2M | 6.44% |
1,720,902
-1,152,098
| -40% | -$25.4M |
|
3
UnitedHealth
UNH
$380B
| $26.4M | 5.46% |
50,500
-9,500
| -16% | -$4.86M |
|
4
CG Oncology
CGON
$6.44B
| $24M | 4.95% |
980,942
-116,858
| -11% | -$3.29M |
|
5
Humana
HUM
$49B
| $21.4M | 4.42% |
81,000
-8,200
| -9% | -$2.22M |
|
|
6
CALL
Humana
HUM
$49B
| $21.2M | 4.37% |
+80,000
| New | +$21.6M |
|
7
Natera
NTRA
$39.7B
| $16.9M | 3.48% |
119,200
-104,600
| -47% | -$16.8M |
|
|
8
Regeneron Pharmaceuticals
REGN
$69.7B
| $16.1M | 3.32% |
25,400
+17,000
| +202% | +$11.7M |
|
|
EXAS
9
DELISTED
Exact Sciences
EXAS
| $15.3M | 3.15% |
353,000
-250,011
| -41% | -$12.7M |
|
|
10
Beam Therapeutics
BEAM
$3.17B
| $13.9M | 2.86% |
+709,517
| New | +$18.6M |
|
11
Glaukos
GKOS
$9.21B
| $13.2M | 2.72% |
134,000
-36,000
| -21% | -$4.8M |
|
12
DexCom
DXCM
$28.1B
| $12.3M | 2.54% |
180,000
-138,000
| -43% | -$11.3M |
|
13
Ultragenyx Pharmaceutical
RARE
$3.12B
| $11.7M | 2.41% |
322,100
-29,900
| -8% | -$1.24M |
|
14
Syndax Pharmaceuticals
SNDX
$2.08B
| $11.4M | 2.34% |
925,000
-575,000
| -38% | -$8.11M |
|
|
15
Cencora
COR
$57.7B
| $10.9M | 2.25% |
+39,300
| New | +$9.87M |
|
|
16
Jazz Pharmaceuticals
JAZZ
$15B
| $9.93M | 2.05% |
80,000
-154,500
| -66% | -$20.2M |
|
17
Tenet Healthcare
THC
$16.6B
| $9.68M | 2% |
72,000
-65,000
| -47% | -$8.56M |
|
18
Neurocrine Biosciences
NBIX
$17.3B
| $9.48M | 1.95% |
85,700
-134,700
| -61% | -$17.1M |
|
19
Danaher
DHR
$142B
| $9.12M | 1.88% |
44,500
-22,500
| -34% | -$4.91M |
|
20
Axsome Therapeutics
AXSM
$12.2B
| $8.98M | 1.85% |
77,000
-111,000
| -59% | -$12.6M |
|
21
CALL
Genmab
GMAB
$17.9B
| $8.48M | 1.75% |
+433,100
| New | +$9.08M |
|
22
Insmed
INSM
$23.8B
| $8.16M | 1.68% |
107,000
-125,800
| -54% | -$9.62M |
|
23
Organon & Co
OGN
$3.54B
| $7.97M | 1.64% |
+535,000
| New | +$8.23M |
|
24
Thermo Fisher Scientific
TMO
$199B
| $7.71M | 1.59% |
15,500
-29,100
| -65% | -$15.8M |
|
25
Xenon Pharmaceuticals
XENE
$6.55B
| $7.68M | 1.58% |
229,000
-245,000
| -52% | -$9.3M |
|
Similar funds
NM
LM
IF
PWAM
CM
LJAC
PO
SH